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Abstract A new formulation of a micronized acetylsali-
cylic acid swallowable tablet with an effervescent
component (FR-aspirin) was evaluated in two independent
studies using the dental impaction pain model. These clin-
ical studies were performed to confirm the results of
preclinical dissolution studies and human pharmacokinetic
studies, which indicated an improved onset of analgesia
without compromising duration of effect or safety. Study 1
evaluated a 650-mg dose of aspirin and Study 2 evaluated a
1,000-mg dose of aspirin. Both studies were double-blin-
ded, parallel group and compared to regular aspirin
(R-aspirin) and placebo. Speed of onset was measured by
the double stopwatch method for time to both first percep-
tible relief and meaningful relief. In both studies, the
FR-aspirin was significantly faster (p \ 0.038–0.001) than
both R-aspirin and placebo for both onset measures. There
were no significant differences between FR-aspirin and
R-aspirin for peak or total effects and both treatments were
significantly better than placebo. For first perceptible relief,
FR-aspirin onset was 19.8 and 16.3 min for 650 mg and
1,000 mg, respectively, compared to 23.7 and 20.0 for
R-aspirin. For meaningful relief, FR-aspirin onset was 48.9
and 49.4 min for 650 mg and 1,000 mg, respectively,
compared to 119.2 and 99.2 for R-aspirin. These efficacy
studies clearly demonstrate that the onset of analgesic
efficacy is dramatically improved by adding an effervescent
component and micronized active ingredient to the swal-
lowable tablet aspirin formulation. The enhanced onset did
not adversely impact either the peak effect or duration of
effect or tolerability compared to regular aspirin.
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Introduction
The two efficacy studies described in this paper were
conducted to evaluate the speed of relief onset from a new
aspirin swallowable tablet formulation compared to regular
aspirin. Based on the improved dissolution and pharma-
cokinetic profile, the expectation was that this formulation
would have a clinically meaningful advantage in time to
onset of pain relief.
Self-treatment of acute mild-to-moderate pain with
over-the-counter (OTC) analgesics is well established in
the general population. Aspirin (acetylsalicylic acid, ASA)
is one of the most commonly used analgesics worldwide
for this purpose. Its efficacy has been shown in several
acute pain conditions, including tension-type headache
(Steiner et al. 2003; Martinez-Martin et al. 2001; Mac-
Eachern et al. 2002), migraine headache (MacGregor et al.
2002; Lange et al. 2000; Diener et al. 2004a, b, 2006;
Lipton et al. 2005; Lampl et al. 2007), sore throat (Eccles
et al. 2003), primary dysmenorrhea (Zhang and Li Wan Po
1998) and dental pain (Forbes et al. 1991, 1992; Cooper
1981a, b), as well as fever (Bachert et al. 2005).
The key domains recognized by consumers for an effi-
cacious acute analgesic are fast onset, long duration and
complete pain relief. Fast onset of action is of particular
importance in an outpatient, self-medication environment.
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Several pain models have been performed to assess pain
relief and onset of relief (Cooper 1983); however, the
Dental Impaction Pain Model (DIPM) is the most well
established. The sensitivity, reproducibility and reliability
of this model are well documented (Cooper and Desjardins
2010; Desjardins et al. 2002). The American Food and
Drug Administration and the European Medicines Agency
both identified the third molar extraction dental pain model
as acceptable for assessing analgesia in acute mild-to-
moderate pain (Food and Drug Administration 1977;
European Medicines Agency 2002).
A novel aspirin formulation with an effervescent com-
ponent consisting of sodium carbonate and micronized
active ingredient has been developed. This new swallow-
able tablet formulation has been shown to decrease
substantially the in vitro dissolution time and in vivo time
to maximum plasma concentration The small active
ingredient particle size provides a much larger surface area
than the Aspirin regular tablet resulting in faster disso-
lution and consequently faster in vivo absorption (Voelker
2011).
Two tablet strengths of the new formulation fast release
(FR-aspirin) contain either 325 or 500 mg aspirin, resulting
in a total dose of either 650 or 1,000 mg. In these two
efficacy studies, we investigated whether the pharmaceu-
tical and pharmacokinetic properties were associated with a
faster onset of pain relief compared to a corresponding
strength of regular Aspirin 325 mg or 500 mg (R-aspirin).
Methods
The studies were designed to evaluate the analgesic effi-
cacy of a single, oral dose of FR-aspirin tablets compared
to R-aspirin tablets and placebo in subjects with postsur-
gical pain resulting from the surgical removal of impacted
third molars. Patients were required to have one of the
following surgical procedures: either two partial bony
impacted mandibular third molars, one full bony impacted
mandibular third molar, or one partial bony impacted and
one fully bony impacted mandibular third molars removed.
Additionally, any maxillary third molars could have been
removed regardless of impaction level.
Each study was conducted at a single study site. For
Study 1, the treatment arms were: placebo, R-aspirin
1,000 mg, FR-aspirin 1,000 mg. For Study 2, the treatment
arms were: placebo, R-aspirin 650 mg, FR-aspirin 650 mg.
Both were randomized, double-blind, parallel group and
single-dose studies. The randomization scheme in both
studies was 2:2:1 for the ratio of active drugs to placebo.
Because the FR-aspirin and R-aspirin tablets were not
identical in appearance, subjects had a blinding device
applied and the study drugs were administered by a third
party who was not otherwise involved in the conduct of the
study. The aspirin comparator was commercially available
Aspirin regular tablet 500 mg or Bayer Aspirin 325 mg
tablets (both Bayer HealthCare, Germany).
Studies were conducted according to the principles of
the International Conference on Harmonisation Harmo-
nised Tripartite Guideline E6(R1): Good Clinical Practice
(GCP), the World Medical Association Declaration of
Helsinki and its most recent amendments, and United
States Title 21 of the Code of Federal Regulations Parts 50
and 56 concerning informed consent and IRB regulations.
Written informed consent was obtained from each subject
at screening before the initiation of any study-related
procedures.
Patients were included in the studies if they had mod-
erate or severe postsurgical pain within 1–4 h after surgery
and a score of C5 on the 11-point numerical pain intensity
rating scale (NRS) (0 = no pain to 10 = very painful).
Patients were provided with two stopwatches starting
at study drug administration: the first was stopped when
they first felt any perceptible pain relief and the second
was pressed when they felt pain relief that was in
their estimation meaningful. The patients recorded pain
intensity (PI) and pain relief (PR) at 10, 20, 30, 40, 50
and 60 min and at 2, 3, 4, 5 and 6 h after dosing. PI
was rated on a four-point categorical pain intensity
scale (0 = no pain, 1 = mild pain, 2 = moderate pain,
3 = severe pain); PR was rated using a five-point cate-
gorical pain relief rating scale (0 = no relief, 1 = a
little relief, 2 = some relief, 3 = a lot of relief, and
4 = complete relief). At the 6-h observation or at the
time of rescue analgesic if it occurred prior to the 6th h
observation, subjects completed a five-point categorical
global evaluation of the study drug (0 = poor, 1 = fair,
2 = good, 3 = very good, and 4 = excellent). Rescue
medication was Lortab 5 (hydrocodone 5 mg/acetamino-
phen 500 mg) tablets. Adverse events were monitored
and recorded throughout the dosing period. After com-
pletion of the dosing period, the study sites had the
option of either contacting subjects within 2–5 days or
scheduling subjects for a follow-up office appointment to
assess surgical healing, the occurrence or persistence of
adverse events and medications taken. The primary effi-
cacy end point was time to first perceptible pain relief.
Secondary variables were time to meaningful PR, PI and
PI differences, summed pain intensity differences (SPID)
and total pain relief (TOTPAR) values at 2, 4 and 6 h
and global evaluation.
Statistical analysis
A sample size calculation for each study of approximately
500 subjects (200 subjects per aspirin treatment group and
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100 subjects in the placebo group) provided 90% power to
detect a treatment difference between FR-aspirin and
R-aspirin for time to pain relief at a two-sided significance
level of 0.05.
All hypotheses were tested at a two-sided significance
level of 0.05. Efficacy variables were analyzed using all
randomized subjects who took the study drug and who had
at least one post-dose assessment on an efficacy parameter
(intent to treat).
Time to first perceptible PR and meaningful PR were
plotted using the Kaplan–Meier method and compared
between treatment groups using the log-rank test. Median
times to first perceptible PR and meaningful PR were
calculated and presented.
Time-weighted SPIDs and TOTPARs were calculated
for 6 h. An analysis of covariance (ANCOVA) model was
used to compare means across treatment groups for the
following secondary efficacy end points: SPID0–2, SPID0–4,
SPID0–6, TOTPAR0–2, TOTPAR0–4, TOTPAR0–6 and PID
at each post-dose time point. The ANCOVA model inclu-
ded treatment and center as the fixed effects and baseline
pain as the covariate. In each analysis, adjusted least
squares (LS) mean standard error and LS mean difference,
along with 95% confidence intervals (CIs) of the differ-
ence, were obtained from the model.
Results of Study 1: 500 mg aspirin tablet
Efficacy evaluations were made on the basis of the 514
patients included in the intent-to-treat (ITT) population for
Study 1 (500 mg of aspirin). There were no group differ-
ences with respect to age, gender and baseline pain
intensity (Table 1). The majority of patients were of
younger age with a range of means of 22.4–22.7 years for
the three treatment groups. At baseline, the overall mean PI
score was 6.6 on the 11-point NRS. Approximately, 80% of
patients in this study graded their baseline pain as moderate
and 20% as severe. Approximately, three-quarters of the
patients underwent removal of two impacted mandibular
molars with a majority of patients having a total of three
molars removed (Table 1).
Kaplan–Meier plots of time to first perceptible pain
relief and meaningful pain relief showed a statistically
significant difference between FR-aspirin tablets and
R-aspirin tablets (p \ 0.05). Both active treatments were
significantly faster than placebo (p \ 0.001) (Figs. 1, 2;
Table 2). Median time to first perceptible pain relief was
16.3 min for FR-aspirin 500 mg and 20.0 min for R-aspirin
500 mg. Median time to meaningful pain relief was
49.4 min for FR-aspirin versus 99.2 min for R-aspirin.
A higher percentage of patients in the FR-aspirin group
achieved pain relief compared to R-aspirin and placebo
(first perceptible pain relief: 92.2 vs. 85.7 vs. 70.5% and
meaningful relief: 65.0 vs. 62.1 vs. 37.1%).
The SPID and TOTPAR results were consistent with the
greater efficacy for the FR-aspirin compared to the
R-aspirin and placebo. At 2 h, differences between FR-
aspirin and R-aspirin were significant [p = 0.026 (SPID)
and p = 0.018 (TOTPAR)] and both actives were statisti-
cally superior compared with placebo (p \ 0.001). For the
4- and 6-h measurements, SPID and TOTPAR for the FR-
aspirin and R-aspirin were not different from each other,
but both were statistically significantly greater than placebo
(Table 2).
With respect to the global evaluation, the majority of
subjects treated with FR-aspirin and R-aspirin rated their
treatment as ‘‘fair’’ or better; while the majority of subjects
treated with placebo rated their treatment as poor. More
subjects treated with FR-aspirin assessed as very good or
excellent (18.0 and 6.3%) compared with R-aspirin [13.8
and 5.4% (Table 3)].
Both active treatments were well tolerated. No serious
adverse events were reported and no subject was discon-
tinued due to adverse event in either 500 mg aspirin
treatment group.
Results of Study 2: 325 mg aspirin tablet
Efficacy evaluations were made on the basis of the 500
patients included in the intent-to-treat (ITT) population for
Study 2 (325 mg aspirin). There were no group differences
with respect to age, gender and baseline pain intensity
(Table 1). The majority of patients were of younger age
with a range of means of 20.3–20.8 years for the three
treatment groups. At baseline, the overall mean PI score
was 7.4 on the 11-point NRS. Approximately, 57% of
patients graded moderate baseline pain and 43% severe
baseline pain. Approximately, three-quarters of patients
underwent removal of two impacted mandibular molars
with a majority of patients having a total of four molars
removed (Table 1).
Kaplan–Meier plots of time to first perceptible pain
relief and meaningful pain relief showed a statistically
significant difference between FR-aspirin tablets and
R-aspirin tablets (p \ 0.05). Both active treatments were
significantly faster than placebo (p \ 0.001) (Figs. 1, 2;
Table 2). Median time to first perceptible pain relief was
19.8 min for FR-aspirin 325 mg and 23.7 min for R-aspirin
325 mg. In this study, median time to meaningful pain
relief was 48.9 min for FR-aspirin versus 119.2 min for
R-aspirin. A higher percentage of patients in the FR-aspirin
group achieved pain relief compared to R-aspirin and
placebo (first perceptible pain relief: 95.0 vs. 85.0 vs.
62.0% and meaningful relief: 72.5 vs. 59.0 vs. 30.0%).
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The SPID and TOTPAR measurements showed the same
consistent pattern as Study 1 for the comparisons between
FR-aspirin, R-aspirin and placebo. At 2 h, differences
between FR-aspirin and R-aspirin were significant
(p \ 0.001 SPID and TOTPAR) and both actives were
statistically superior compared with placebo (p \ 0.001).
Table 1 Summary of demographics and baseline characteristics
Study Variable Aspirin fast-release tablet Aspirin regular tablet Placebo
500 mg (Study 1) ITT population 206 203 105
Age, [years (mean ? SD)] 22.4 (4.62) 22.7 (4.85) 22.5 (4.24)
Gender ratio, male:female (%) 44.7:55.3 41.9:58.1 50.5:49.5
11-point intensity [mean (SD)] 6.6 (1.14) 6.5 (1.07) 6.6 (1.17)
Categorical pain intensity (%)
Moderate 80.6 80.3 79.0
Severe 19.4 19.7 21.0
Number of molars removed (%)
1 17.0 21.2 17.1
2 82.0 78.3 79.0
3 1.0 0.5 3.8
Tooth sites (%)a
Left upper third molar 35.9 32.5 35.2
Left lower third molar 43.7 38.9 41.0
Right upper third molar 46.6 48.8 50.5
Right lower third molar 57.8 59.1 60.0
Impaction score (%)a
Erupted in tissue 23.3 26.6 24.8
Broken soft tissue 10.2 13.8 21.0
Partial bony impaction 38.3 32.5 29.5
Full bony impaction 85.9 86.7 85.7
325 mg (Study 2) ITT population 200 200 100
Age, years [mean (SD)] 20.3 (3.33) 20.8 (4.05) 20.7 (3.57)
Gender ratio, male:female (%) 31.5:68.5 41.5:58.5 34.0:66.0
11-point intensity [mean (SD)] 7.3 (1.30) 7.4 (1.35) 7.5 (1.40)
Categorical pain intensity (%)
Moderate 57.0 55.5 56.0
Severe 43.0 44.5 44.0
Number of molars removed (%)
1 6.0 3.0 8.0
2 87.5 88.0 88.0
3 0 0 0
4 6.5 9.0 4.0
Tooth sites (%)a
Left upper third molar 66.0 59.0 61.0
Left lower third molar 69.0 65.0 68.0
Right upper third molar 65.5 66.5 61.0
Right lower third molar 68.5 73.5 66.0
Impaction score (%)a
Erupted in tissue 9.0 8.5 14.0
Broken soft tissue 5.5 8.5 8.0
Partial bony impaction 45.0 50.0 41.0
Full bony impaction 84.5 79.5 88.0
a Patients may have had more than one affected tooth site or impaction score
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Similar to Study 1, for the 4- and 6-h SPID and TOTPAR
measurements, the aspirin groups were not different;
whereas both were statistically significantly greater than
placebo (Table 2).
With respect to global evaluation, the majority of sub-
jects treated with FR-aspirin and R-aspirin assessed as
‘‘fair’’ or better; while the majority of subjects treated with
placebo assessed as ‘‘poor’’. More subjects treated with
FR-aspirin assessed as very good or excellent (22.0 and
12.5%) compared with R-aspirin [19.5 and 8.9%
(Table 3)].
Both active treatments were well tolerated. In this study,
there was one aspirin 325 mg subject in the R-aspirin
group, who experienced a serious adverse event of gastritis
that was considered not related to the study drug, and two
subjects (1 in the R-aspirin group and 1 in the placebo
group) who discontinued due to non-serious adverse
events.
Fig. 1 Kaplan–Meier plot of time to first perceptible and meaningful pain relief from aspirin 500 mg
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In both studies, the percentages of patients taking res-
cue medication (1,000 mg study: FR-aspirin = 57.8%,
R-aspirin = 49.8%, placebo = 68.6% and 650 mg study:
FR-aspirin = 59.0%, R-aspirin = 51.0%, placebo = 72.0%)
and the median times to rescue medication (1,000 mg study:
FR-aspirin = 252 min, R-aspirin [ 360 min, placebo =
124 min and 650 mg study: FR-aspirin = 268 min,
R-aspirin = 322 min, placebo = 105 min) were not sta-
tistically significantly different between active treatments,
but both actives were significantly better than placebo
(p \ 0.001).
Safety results
Adverse events of the individual studies are shown in
Table 4. In Study 1, between 15 and 22% of subjects
experienced at least one adverse event; in Study 2,
Fig. 2 Kaplan–Meier plot of time to first perceptible and meaningful pain relief from aspirin 325 mg
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Table 2 Time to relief and efficacy results
Study Variable Aspirin fast-release tablet Aspirin regular tablet Placebo
500 mg (Study 1) Median time to FPR, min (95% CI) 16.3 (12.2, 19.2) 20.0 (15.7, 23.4) 20.0 (18.9. 30.0)
p value versus fast-release aspirin – 0.004 \0.001
p value versus regular aspirin – – 0.014
% of subjects achieved PR 92.2 85.7 70.5
% of subjects censored 7.8 14.3 29.5
Median time to MR, min (95% CI) 49.4 (40.2, 57.7) 99.2 (77.0, 148.3) NA (NA, NA)
p value versus fast-release aspirin – 0.038 \0.001
p value versus regular aspirin – – \0.001
% of subjects achieved PR 65.0 62.1 37.1
% of subjects censored 35.0 37.9 62.9
SPID 0–2 h, mean (SD) 1.3 (1.5) 1.0 (1.5) 0.2 (1.3)
p value versus fast-release aspirin – 0.026 \0.001
p value versus regular aspirin – – \0.001
SPID 0–4 h, mean (SD) 1.9 (3.2) 2.0 (3.4) 0.3 (3.2)
p value versus fast-release aspirin – 0.922 \0.001
p value versus regular aspirin – – \0.001
SPID 0–6 h, mean (SD) 2.3 (4.7) 2.8 (5.3) 0.5 (5.2)
p value versus fast-release aspirin – 0.403 0.003
p value versus regular aspirin – – \0.001
TOTPAR 0–2 h, mean (SD) 3.3 (2.2) 2.8 (2.2) 1.7 (2.0)
p value versus fast-release aspirin – 0.018 \0.001
p value versus regular aspirin – – \0.001
TOTPAR 0–4 h, mean (SD) 5.7 (4.5) 5.6 (4.8) 3.5 (4.6)
p value versus fast-release aspirin – 0.882 \0.001
p value versus regular aspirin – – \0.001
TOTPAR 0–6 h, mean (SD) 7.6 (6.6) 8.0 (7.5) 5.5 (7.6)
p value versus fast-release aspirin – 0.463 0.013
p value versus regular aspirin – – 0.002
325 mg (Study 2) Median Time to FPR, min (95% CI) 19.8 (18.2, 20.0) 23.7 (19.2, 30.0) 41.4 (30.7 103.9)
p value versus fast-release aspirin – \0.001 \0.001
p value versus regular aspirin – – \0.001
% of subjects achieved PR 95.0 85.0 62.0
% of subjects censored 5.0 15.0 38.0
Median time to MR, min (95% CI) 48.9 (41.8, 54.5) 119.2 (93.6, 192.3) NA (NA, NA)
p value versus fast-release aspirin – \0.001 \0.001
p value versus regular aspirin – – \0.001
% of subjects achieved PR 72.5 59.0 30.0
% of subjects censored 27.5 41.0 70.0
SPID 0–2 h, mean (SD) 1.7 (1.6) 1.2 (1.5) 0.1 (1.2)
p value versus fast-release aspirin – \0.001 \0.001
p value versus regular aspirin – – \0.001
SPID 0–4 h, mean (SD) 2.8 (3.5) 2.7 (3.4) 0.3 (2.7)
p value versus fast-release aspirin – 0.668 \0.001
p value versus regular aspirin – – \0.001
SPID 0–6 h, mean (SD) 3.5 (5.4) 3.8 (5.3) 0.6 (4.5)
p value versus fast-release aspirin – 0.631 \0.001
p value versus regular aspirin – – \0.001
TOTPAR 0–2 h, mean (SD) 3.6 (2.1) 2.7 (2.1) 1.1 (1.4)
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between 14 and 18%. Gastrointestinal adverse events
appeared between 4 and 8% in Study 1 and between 5 and
8% in Study 2. The most common GI adverse event was
nausea.
Discussion
If an analgesic works fast, the consumers get the relief they
seek and then there is less likelihood of taking additional
medication that can result in unwanted side effects. In the
recent past, several OTC analgesics were introduced as
softgel or liquigel formulations with the putative advantage
of a faster onset of action (Doyle et al. 2002). Interestingly,
to our knowledge, none of these analgesics has ever
directly compared the new formulation to the original
formulation in a double-blinded efficacy study. These
drugs rely on dissolution and pharmacokinetic data to
justify their putative onset advantage; but this is not nec-
essarily directly correlated into a clinical advantage. In the
two studies presented, the efficacy data clearly demonstrate
that the new formulation of aspirin has a faster onset of
action at both the 650 mg and 1,000 mg doses. For the
aspirin 650 mg dose, the median time to meaningful relief
was 70.3 min faster than regular aspirin, and for the
1,000 mg aspirin dose, the median time to meaningful
relief was 49.8 min faster than regular aspirin. From a
clinical standpoint, this is a very relevant advantage and
was accomplished without the addition of any active
adjuvant such as caffeine. This advanced aspirin formula-
tion was accomplished by incorporating an effervescent
component (sodium carbonate) and micronized active
ingredient. Unlike a softgel or liquigel formulation, this
aspirin formulation retains the advantage of still being a
tablet.
Furthermore, the overall efficacy of the FR-aspirin tablet
was sustained as shown by the non-significant differences
between FR-aspirin and R-aspirin for the SPID- and
TOTPAR measurements and the use of rescue medication
over the 6-h observation period.
The dental impaction pain model was chosen for these
studies because of its proven validity, reliability and sen-
sitivity. The results of these two studies are consistent with
previous dental studies and there was a strong correlation
between the improved pharmacokinetics of the new aspirin
formulation and clinical efficacy.
It can be postulated that the minor outcome differences
between the two studies can be explained by the expected
variability between the two different study sites. Further-
more, distribution of baseline pain intensity was different
in the two studies. However, the results of the two studies
were remarkably consistent and supportive of the faster
onset for the FR-aspirin formulations.
Table 2 continued
Study Variable Aspirin fast-release tablet Aspirin regular tablet Placebo
p value versus fast-release aspirin – \0.001 \0.001
p value versus regular aspirin – – \0.001
TOTPAR 0–4 h, mean (SD) 6.3 (4.8) 6.0 (4.8) 2.3 (3.4)
p value versus fast-release aspirin – 0.437 \0.001
p value versus regular aspirin – – \0.001
TOTPAR 0–6 h, mean (SD) 8.5 (7.4) 8.6 (7.4) 3.7 (5.7)
p value versus fast-release aspirin – 0.875 \0.001
p value versus regular aspirin – – \0.001
FPR first perceptible pain relief, MR meaningful relief, CI confidence interval, SPID summed pain intensity differences, TOTPAR total pain
relief. NA not available









500 mg (Study 1) Poor 25.7 31.5 58.1
Fair 26.2 20.7 13.3
Good 22.3 28.1 19.0
Very good 18.0 13.8 5.7
Excellent 6.3 5.4 2.9
325 mg (Study 2) Poor 19.5 29.0 60.0
Fair 16.5 18.5 17.0
Good 29.0 24.0 16.0
Very good 22.0 19.5 5.0
Excellent 12.5 8.0 0.0
240 S. A. Cooper, M. Voelker
123
Conclusions
The two efficacy studies described in this paper clearly
demonstrate that the onset of analgesic efficacy is
improved by adding an effervescent component (sodium
carbonate) and micronized active ingredient to the aspirin
formulation. The enhanced onset did not adversely impact
either the peak effect or duration of effect compared to
regular aspirin. In addition, the side effect data from these
single dose studies did not indicate any change in the side
effect profile. The initial findings of significantly improved
dissolution and pharmacokinetic profiles for this new rap-
idly acting aspirin formulation were confirmed in these two
well-controlled efficacy studies.
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